MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia

[1]  K. Kelsey,et al.  CYP1A1 variants and smoking‐related lung cancer in San Francisco bay area Latinos and African Americans , 2005, International journal of cancer.

[2]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[3]  L. Clegg,et al.  SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia. , 2002, Medical and pediatric oncology.

[4]  B. Christensson,et al.  MDM2 AND p53 IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: Higher Expression in Childhood Leukemias with Poor Prognosis Compared to Long-Term Survivors , 2001, Pediatric hematology and oncology.

[5]  E. Lukhtanov,et al.  3'-minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures. , 2000, Nucleic acids research.

[6]  M. Spitz,et al.  Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican- and African-Americans. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[7]  J. Shuster,et al.  Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Bartram,et al.  Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. , 1993, Blood.